Page 104 - 2019_08-Haematologica-web

C. Fava et al.
phase myeloid leukaemia patients in sus-
tained complete molecular response: a ran- domised trial of the Dutch-Belgian Cooperative Trial for Haemato-Oncology (HOVON). Eur J Cancer. 2013;49(15):3242- 3246.
12. Lee S-E, Choi SY, Bang J-H, et al. Predictive factors for successful imatinib cessation in chronic myeloid leukemia patients treated with imatinib. Am J Hematol. 2013; 88(6):449-454.
13. Mori S, Vagge E, le Coutre P, et al. Age and dPCR can predict relapse in CML patients who discontinued imatinib: the ISAV study. Am J Hematol. 2015;90(10):910-914.
14. Tsutsumi Y, Ito S, Ohigashi H, Shiratori S, Teshima T. Unplanned discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia. Mol Clin Oncol. 2016;4(1):89-92.
15. Lee S-E, Choi SY, Song H-Y, et al. Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment dis- continuation: the KID study. Haematologica. 2016;101(6):717-723.
16. Yhim H-Y, Lee N-R, Song E-K, et al. Long- Term Outcomes after Imatinib Mesylate Discontinuation in Chronic Myeloid Leukemia Patients with Undetectable Minimal Residual Disease. Acta Haematol. 2016;135(3):133-139.
17. Ferrero D, Cerrano M, Crisà E, Aguzzi C, Giai V, Boccadoro M. How many patients can proceed from chronic myeloid leukaemia diagnosis to deep molecular response and long-lasting imatinib discon- tinuation? A real life experience. Br J Haematol. 2017;176(4):669-671.
18. Imagawa J, Tanaka H, Okada M, et al. Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicen- tre phase 2 trial. Lancet Haematol.
2015;2(12):e528-535.
19. Rea D, Nicolini FE, Tulliez M, et al.
Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study. Blood. 2017;129(7):846-854.
20. Hochhaus A, Masszi T, Giles FJ, et al. Treatment-free remission following front- line nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study. Leukemia. 2017;31(7):1525-1531
21. Saussele S, Richter J, Guilhot J, et al. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicen- tre, non-randomised, trial. Lancet Oncol. 2018;19(6):747-757.
22. Mahon FX, Nicolini FE, Noel MP, et al. Preliminary report of the STIM2 study: a multicenter stop imatinib trial for chronic phase chronic myeloid leukemia de novo patients on imatinib [abstract]. Blood. 2013; 122(21):654.
23. Takahashi N, Tauchi T, Kitamura K, et al. Deeper molecular response is a predictive factor for treatment-free remission after imatinib discontinuation in patients with chronic phase chronic myeloid leukemia: the JALSG-STIM213 study. In J Hematol. 2018;107(2):185-193.
24. Shah NP, Paquette R, Müller MC, et al. Treatment-free remission (TFR) in patients with chronic phase chronic myeloid leukemia (CMLCP) and in stable deep molecular response (DMR) to dasatinib: the Dasfree Study. Blood. 2016; 128(22):1895.
25. Hughes TP, Boquimpani CM, Takahashi N, et al. Treatment-free remission in patients with chronic myeloid leukemia in chronic phase according to reasons for switching from imatinib to nilotinib: subgroup analy- sis from ENESTop. Blood. 2016; 128(22):792.
26. Cross NC, White HE, Colomer D, et al. Laboratory recommendations for scoring deep molecular responses following treat- ment for chronic myeloid leukemia. Leukemia. 2015;29(5):999-1003.
27. Baccarani M, Deininger MW, Rosti G, et al. LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122(6):872-884.
28. Sander Greenland, Rhian Daniel, Neil Pearce; Outcome modelling strategies in epidemiology: traditional methods and basic alternatives. Int J Epidemiol. 2016;45(2):565-575.
29. Vatcheva KP, Lee M, McCormick JB, Rahbar MH. Multicollinearity in Regression Analyses Conducted in Epidemiologic Studies. Epidemiology (Sunnyvale). 2016;6(2).
30. R Core Team (2017). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria
31. Legros L, Nicolini FE, Etienne G, et al. Second tyrosine kynase inhibitor discontin- uation attempt in patients with chronic myeloid leukemia. Cancer. 2017; 123(22):4403-4410.
32. Kong JH, Winton EF, Heffner LT, et al. Does the frequency of molecular monitoring after tyrosine kynase inhibitor discontinua- tion affect outcomes of patients with chronic myeloid leukemia? Cancer. 2017;123(13):2482-2488.
33. http://www.ema.europa.eu/docs/en_GB/ document_library/ EPAR_Product_Information/human/00079 8/WC500034394.pdf
34. Hochhaus A, Saussele S, Rosti G, et al. Chronic Myloid Leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol. 2017;28(suppl_4):iv41-iv51.
35. https://www.nccn.org/professionals/physi- cian_gls/pdf/cml.pdf
1596
haematologica | 2019; 104(8)